Nashville, Tennessee
Cancer biologic therapy trials in Nashville, TN
59 cancer biologic therapy studies are recruiting participants at sites in Nashville as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Nashville at a glance
- 59 studies are recruiting at a site in Nashville.
- By phase: Phase 1 (11), Phase 1/2 (10), Phase 2 (17), Phase 2/3 (2), Phase 3 (17), Observational (2).
- By sponsor: industry (41), university, hospital or other (10), government (8).
- By research area: Lymphoma (20), Lung Cancer (15), Breast Cancer (14), Melanoma (5), Prostate Cancer (5).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Nashville
Basic details from each study's public record (the 30 most recently updated of 59). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt Breast Center at One Hundred Oaks
- Registry record
- NCT05422794 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Vanderbilt Breast Center at One Hundred Oaks · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05564377 · updated
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- One Oncology - Tennessee Oncology ( Site 0098) · SCRI Oncology Partners ( Site 7000) · Tennessee Oncology ( Site 0111)
- Registry record
- NCT06393374 · updated
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- SCRI Oncology Partners ( Site 7004) · Tennessee Oncology ( Site 0018)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Nashville General Hospital ( Site 0017) · SCRI Oncology Partners ( Site 7005) · Vanderbilt-Ingram Cancer Center ( Site 0038)
- Registry record
- NCT06966700 · updated
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06797635 · updated
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
- Phase 1
- Ages 18 and older
- Female participants
- Sponsor
- Immunomic Therapeutics, Inc.
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07652242 · updated
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- SCRI Oncology Partners ( Site 7000) · Tennessee Oncology ( Site 0068)
- Registry record
- NCT07060807 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Lung cancer studies recruiting in Nashville
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Summit Therapeutics
- Study site
- Clinical Study Sites
- Registry record
- NCT06767514 · updated
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Elliston Place Medical Oncology & Hematology ( Site 0215)
- Registry record
- NCT06623422 · updated
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
- Registry record
- NCT07221474 · updated
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06646276 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Nashville
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT03866382 · updated
JUR-003 in Adult Patients With Metastatic Prostate Cancer
- Phase 1
- Ages 18 and older
- Male participants
- Sponsor
- Juri Biosciences, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07824349 · updated
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Phase 3
- Ages 18 and older
- Male participants
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Tennessee Oncology Nashville
- Registry record
- NCT07164443 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- Sarah Cannon Research
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nashville, TN on ClinicalTrials.gov.
Melanoma studies recruiting in Nashville
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Lymphoma studies recruiting in Nashville
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Phase 2
- Up to 365 days
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT06317662 · updated
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT06717347 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7002)
- Registry record
- NCT06890884 · updated
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Henry-Joyce Cancer Clinic ( Site 0115) · SCRI Oncology Partners ( Site 0100)
- Registry record
- NCT07519772 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- SCRI Oncology Partners ( Site 7000)
- Registry record
- NCT07634471 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT05675410 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT07003295 · updated
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Umoja Biopharma
- Study site
- Sarah Cannon Research Institute
- Registry record
- NCT07735533 · updated
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Study site
- Sarah Cannon Research Institute Oncology Partners
- Registry record
- NCT07015242 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- SCRI Oncology Partners
- Registry record
- NCT07188558 · updated
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Allogene Therapeutics
- Study site
- Vanderbilt University Medical Center
- Registry record
- NCT06500273 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- The Children's Hospital at TriStar Centennial · Vanderbilt University/Ingram Cancer Center
- Registry record
- NCT06124157 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nashville, TN on ClinicalTrials.gov.
Ask about studies near Nashville
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections